Key clinical point: Activity of first-line nivolumab-ipilimumab therapy in microsatellite instability–high/DNA mismatch repair–deficient colorectal cancer was sustained longer term.
Major finding: At a median follow-up of 19.9 months, the investigator-assessed objective response rate was 64%.
Study details: An update on a cohort of 45 patients with microsatellite instability–high/DNA mismatch repair–deficient metastatic colorectal cancer treated in the first line with combination nivolumab and ipilimumab on a multicohort phase 2 trial (CheckMate 142).
Disclosures: Dr. Lenz reported receiving honoraria from Bayer, Boehringer Ingelheim, Merck Serono, and Roche; consulting or advising with Bayer, Merck Serono, Pfizer, and Roche; receiving travel expenses from Bayer, Merck Serono, and Roche. The trial was funded by Bristol-Myers Squibb. Dr. Sung reported that he had no relevant conflicts of interest.
Lenz H-J et al. 2020 GI Cancers Symposium, Abstract 11.